China Mandates Full UDI Compliance for All Medical Devices by 2029

On March 13, 2026, China’s National Medical Products Administration (NMPA), together with the National Health Commission and the National Healthcare Security Administration, issued the “Announcement on Further Implementing UDI for Subsequent Device Categories (No. 21 of 2026).” Building on “Announcement No. 22 of 2023,” the notice confirms the final phase of China’s nationwide Unique Device Identification (UDI) rollout, with full enforcement extending through 2029.

Under the announcement, UDI data will become a mandatory prerequisite for product registration, renewal, and modification. Products that are not assigned UDI codes and do not upload data on time will fail regulatory review, facing the risk of being unable to enter the market or having their registration certificates revoked.

China Completes Full UDI Coverage Across All Medical

The announcement completes China’s three-stage UDI implementation, extending requirements to all remaining device categories and closing prior regulatory gaps.

Previously limited to Class III and selected Class II devices, China UDI requirements now apply to:

• All Class II medical devices
• All Class I medical devices
• In vitro diagnostic (IVD) reagents

Manufacturers must assign UDI codes at the smallest sales unit and upload data before submitting applications. Failure to comply with NMPA UDI requirements may result in:

• Rejected registrations or filings
• Denied renewals
• Potential loss of existing approvals

Limited Exemptions Introduced for Specific Product Types

While China expands UDI requirements, regulators have introduced limited exemptions for specific product categories.

“Announcement No. 15 of 2026” allows exemptions for certain devices, including custom-made medical devices and products intended solely for research use. Manufacturers must assess eligibility carefully and maintain supporting documentation to ensure compliance with NMPA expectations.

Implementation Timeline Sets Binding UDI Deadlines

China’s UDI system rollout is structured around two mandatory deadlines that define when compliance becomes enforceable across device classes.

June 1, 2027:
All Class II medical devices, including IVDs, and all Class I IVD reagents must carry UDI codes. UDI data must be uploaded to the national UDI database before market launch and included in all medical device registration, filing, renewal, and modification submissions.

June 1, 2029:
All Class I medical devices must comply with UDI requirements, including pre-market data submission. At this stage, UDI compliance in China applies to all device categories without exception.

UDI Linked to Reimbursement and Healthcare Data Systems in China

The joint issuance by three national authorities introduces a new compliance dimension — the integration of UDI data with healthcare insurance systems.

For the first time, manufacturers must ensure bidirectional linkage between:

• UDI data
• National healthcare insurance codes for medical consumables and reagents

This “three-medical linkage” connects medical device regulation, healthcare delivery, and reimbursement systems.

Market Implications for Overseas Medical Device Manufacturers

The expansion of China UDI requirements will significantly impact competitive dynamics and compliance expectations.

Higher Compliance Thresholds and Market Consolidation

Full UDI implementation increases technical and regulatory barriers. Manufacturers lacking robust traceability systems may struggle to comply, particularly in low-margin segments.

This may lead to the exit of smaller or less compliant domestic players, creating a more balanced competitive environment for overseas manufacturers with established quality systems.

UDI as a Gateway to Reimbursement and Procurement

UDI is now explicitly linked to reimbursement and national/provincial centralized procurement participation. Products without complete and accurate UDI data will face barriers in:

• Tendering processes at national and provincial levels
• Payment settlement within healthcare insurance systems

Conversely, compliant manufacturers can benefit from faster reimbursement cycles and improved cash flow.

Enhanced Brand Trust Through Traceability

Full lifecycle traceability strengthens product credibility. Devices with complete UDI data are more easily tracked in adverse event scenarios, improving transparency and safety perception. For international brands, this enhances trust among Chinese healthcare providers and patients.

Key Challenges

Despite its long-term benefits, full UDI implementation introduces significant operational complexity, particularly for overseas manufacturers managing large product portfolios.

Many newly included Class I products involve high SKU volumes and limited margins. Assigning UDI codes, updating packaging, and maintaining accurate datasets can create significant cost and resource pressure.

UDI compliance often requires packaging updates across global production sites. Lead times for design, approval, and logistics must be managed carefully to avoid supply disruptions.

Recommended Actions for Overseas Companies

Given the phased implementation timeline, early preparation is critical for maintaining uninterrupted market access.

Overseas manufacturers should prioritize:

• Initiating UDI readiness programs in 2026, particularly for Class II products
• Aligning UDI data with healthcare insurance codes to support reimbursement
• Strengthening coordination with China-based local agents on coding, data submission, and regulatory responsibilities

A proactive approach will reduce compliance risks and ensure timely alignment with NMPA UDI requirements.

Final Thoughts: Preparing for Full UDI Enforcement in China

China’s move to full UDI coverage signals a decisive shift toward data-driven regulation, where product traceability, reimbursement eligibility, and market access are tightly interconnected. What was once a phased compliance requirement has now evolved into a core regulatory infrastructure that underpins how medical devices are approved, monitored, and commercialized across the entire lifecycle.

For overseas manufacturers, the primary challenge lies in managing large product portfolios while aligning UDI data with both regulatory submissions and reimbursement systems under tight timelines.

Addressing these demands requires a structured, end-to-end approach that connects classification, data integrity, and regulatory execution. Cisema supports international companies through an integrated model combining product classification, UDI strategy planning, reimbursement code mapping, and seamless integration into NMPA registration workflows, helping manufacturers achieve compliance efficiently while maintaining uninterrupted market access in China.

For tailored support in navigating China’s UDI requirements, contact Cisema today.

Further Information

Explore Cisema’s services for medical device registration and compliance in China through its dedicated offering for China medical device registration.

For additional regulatory context and prior developments on UDI implementation, read our related articles:

• UDI in China: Most Medical Devices Now Covered Under the Latest NMPA Drafts
• UDI Requirements for the First Batch of Medical Devices
• Unique Identification System (UDI) of Medical Devices
• Pilot Plan of the UDI System in Hainan Launched

References

• “Announcement on UDI Implementation for Specific Situations (No. 15 of 2026)” issued by the NMPA
• “Announcement on Further Implementing UDI for Subsequent Device Categories (No. 21 of 2026)” jointly issued by the NMPA, National Health Commission, and National Healthcare Security Administration
• “UDI Overview Infographic” published by the NMPA